TWI440465B - Herbal extract mixture for reducing blood lipid and a combination thereof - Google Patents

Herbal extract mixture for reducing blood lipid and a combination thereof Download PDF

Info

Publication number
TWI440465B
TWI440465B TW101124040A TW101124040A TWI440465B TW I440465 B TWI440465 B TW I440465B TW 101124040 A TW101124040 A TW 101124040A TW 101124040 A TW101124040 A TW 101124040A TW I440465 B TWI440465 B TW I440465B
Authority
TW
Taiwan
Prior art keywords
extract
yam
sample
acanthopanax
chinese herbal
Prior art date
Application number
TW101124040A
Other languages
Chinese (zh)
Other versions
TW201402139A (en
Inventor
Po Lun Wang
I Min Liu
Shorong Shii Liou
Chia Ju Chang
Original Assignee
Timing Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Timing Pharmaceutical Co Ltd filed Critical Timing Pharmaceutical Co Ltd
Priority to TW101124040A priority Critical patent/TWI440465B/en
Publication of TW201402139A publication Critical patent/TW201402139A/en
Application granted granted Critical
Publication of TWI440465B publication Critical patent/TWI440465B/en

Links

Description

用以降血脂的中草藥萃取混合物及其醫藥組合物Chinese herbal medicine extract mixture for reducing blood fat and pharmaceutical composition thereof

本發明係關於一種中草藥萃取混合物,特別係一種用以降血脂的中草藥萃取混合物及其醫藥組合物。The present invention relates to a Chinese herbal medicine extract mixture, in particular to a Chinese herbal medicine extract mixture for lowering blood fat and a pharmaceutical composition thereof.

社會型態由農業轉工商業活動後,由於活動力的減少及飲食型態的改變,造成現代人的熱量攝取過多,使脂肪在體內囤積,造成現代人容易有高血脂症的情況。一旦體內血脂值居高不下,脂肪會堆積於體內,甚至導致脂肪肝或粥狀動脈硬化的情況,進而併發如中風、動脈硬化或心臟病等腦心血管疾病。由此可知,高血脂症是腦心血管疾病的主要致病因素,應當嚴加控管血脂不超過正常範圍,以降低腦心血管疾病發生的機率。After the social type of business is transferred from agriculture to commercial activities, due to the reduction of activity and changes in diet, modern people's caloric intake is too much, causing fat to accumulate in the body, causing modern people to have high blood lipids. Once the blood lipid level in the body is high, fat will accumulate in the body, and even lead to fatty liver or atherosclerotic arteriosclerosis, and then complicated by cardiovascular diseases such as stroke, arteriosclerosis or heart disease. It can be seen that hyperlipidemia is the main cause of cardiovascular disease, and it should be strictly controlled that blood lipids do not exceed the normal range to reduce the incidence of cardiovascular disease.

除了培養良好生活習慣、盡量減少熱量攝取並提高每日的運動量之外,根據慈濟醫院柯建新中醫師於2004年之人醫心傳期刊發表「為銀髮族的健康把關-高脂血症的中醫療法」一文中,建議高血脂患者可以依照自己的高血脂類型選擇適合的天然中草藥來控制體內血脂含量。In addition to cultivating good living habits, minimizing caloric intake and increasing daily exercise, according to the Tzu Chi Hospital's 2004 Chinese Medicine Journal, "The Health of the Silver-Care" - Hyperlipidemia In the article "Chinese medicine", it is recommended that patients with hyperlipidemia can choose the appropriate natural Chinese herbal medicine according to their high blood lipid type to control the blood lipid content in the body.

根據該文章內容中所述,丹蔘、女貞子及紅花係具有抑制脂肪蓄積的效果,而市面上亦有許多具降血脂功能之天然中草藥或食品,如燕麥、靈芝、珊瑚草、刺五加或山藥等,然而,由於各種天然中草藥或食品中的有效成分含量低,即使高血脂患者每天食用該等中草藥或食品,卻無法確保食用者攝取到該等中草藥或食品中足夠抑制血脂蓄 積細胞的有效成分。According to the content of the article, tannin, scorpion and safflower have the effect of inhibiting fat accumulation, and there are many natural Chinese herbal medicines or foods with hypolipidemic functions such as oats, ganoderma, coral grass and acanthopanax. Or yam, etc. However, due to the low content of active ingredients in various natural Chinese herbal medicines or foods, even if hyperlipidemia patients consume these Chinese herbal medicines or foods every day, they cannot ensure that the intake of such Chinese herbal medicines or foods by the consumers is sufficient to inhibit blood lipid storage. The active ingredient of the accumulated cells.

再者,為了將各類天然中草藥的有效成分含量提高,進一步將各類有效成分提取,而獲得其中草藥萃取物。例如台灣公開第200920390號「具有調節血脂功能之中草藥油溶性萃取物」,係選自肉豆蔻、甘草、川芎、五味子、山植、當歸、丹蔘、白朮、三七、熟地、淮山、杜仲、白果、陳皮、葛根、黃精、枸杞、馬齒莧、決明子及其混合物所組成之群組,以油溶性溶劑萃取而獲得之中草藥油溶性萃取物。然而,該中草藥油溶性萃取物的組合種類繁多,卻無法確認各組合的中草藥之間,其活性成分是否會有互相干擾或抑制其降血脂效果的情況。Furthermore, in order to increase the active ingredient content of various natural Chinese herbal medicines, various active ingredients are further extracted to obtain herbal extracts thereof. For example, Taiwan Public Publication No. 200920390 "oil-soluble extract of herbal medicine with blood lipid regulation function" is selected from the group consisting of nutmeg, licorice, Chuanxiong, Schisandra, Shanzhi, Angelica, Danshen, Atractylodes, Sanqi, Rehmannia, Huaishan, Eucommia, A group consisting of ginkgo, tangerine peel, puerarin, huangjing, medlar, purslane, cassia seed and mixtures thereof, is extracted with an oil-soluble solvent to obtain a Chinese herbal oil-soluble extract. However, the combination of the oil-soluble extract of the Chinese herbal medicine has a wide variety, but it is impossible to confirm whether the active ingredients of the respective combinations of the Chinese herbal medicines interfere with each other or inhibit the blood lipid lowering effect.

本發明之主要目的係提供一種用以降血脂的中草藥萃取混合物,係能夠有效降低腦心血管疾病罹患風險者。The main object of the present invention is to provide a Chinese herbal medicine extract mixture for lowering blood fat, which is capable of effectively reducing the risk of cardiovascular and cardiovascular diseases.

本發明之次一目的係提供一種用以降血脂的中草藥萃取混合物,其中各中草藥萃取物之間具有抑制脂肪蓄積的加乘作用者。A second object of the present invention is to provide a Chinese herbal medicine extract mixture for lowering blood fat, wherein each Chinese herbal medicine extract has a multiplier for inhibiting fat accumulation.

本發明之又一目的係提供一種用以降血脂的醫藥組合物,其係包含有三種中草藥萃取物能夠互相產生協同作用而提高降血脂效果者。Still another object of the present invention is to provide a pharmaceutical composition for lowering blood fat, which comprises three kinds of herbal extracts capable of synergistically acting on each other to enhance the blood fat lowering effect.

為達到前述發明目的,本發明所運用之技術內容包含有:一種用以降血脂的中草藥萃取混合物,係包含:一重量百分比為33.4~77.7%之珊瑚草萃取物;一重量百分比為 11.14~33.3%之刺五加萃取物;及一重量百分比為11.14~33.3%之山藥萃取物。In order to achieve the foregoing object, the technical content of the present invention comprises: a Chinese herbal medicine extract mixture for lowering blood fat, comprising: a weight percentage of 33.4 to 77.7% of coral grass extract; 11.14~33.3% of acanthopanax extract; and a percentage by weight of 11.14~33.3% of yam extract.

其中,該珊瑚草萃取物、該刺五加萃取物及該山藥萃取物較佳係藉由下列步驟而製得:一萃取步驟,以水作為萃取溶劑,分別對珊瑚草樣本、刺五加樣本及山藥樣本進行萃取,而獲得一珊瑚草萃取液、一刺五加萃取液及一山藥萃取液,其中,該萃取溶劑分別與該珊瑚草樣本、該刺五加樣本及該山藥樣本之重量比例為1:8~1:12;一濃縮步驟,係分別將該珊瑚草萃取液、該刺五加萃取液與該山藥萃取液進行濃縮,分別得到一珊瑚草萃取物、一刺五加萃取物與一山藥萃取物;及一混合步驟,將該珊瑚草萃取物、該刺五加萃取物與該山藥萃取物混合成該中草藥萃取混合物。Wherein, the coral grass extract, the acanthopanax extract and the yam extract are preferably obtained by the following steps: an extraction step, using water as an extraction solvent, respectively for the coral grass sample, the acanthopanax sample And extracting the yam sample to obtain a coral grass extract, a acanthopanax extract and a yam extract, wherein the extraction solvent is respectively proportional to the weight ratio of the coral grass sample, the acanthopanax sample and the yam sample It is 1:8~1:12; in a concentration step, the coral grass extract, the acanthopanax extract and the yam extract are separately concentrated to obtain a coral grass extract and a acanthopanax extract. And a yam extract; and a mixing step, mixing the coral grass extract, the acanthopanax extract with the yam extract into the Chinese herbal extract mixture.

其中該珊瑚草樣本、該刺五加樣本及該山藥樣本可以選擇為未經乾燥或曝曬的鮮品、乾燥物或炮製物。The coral grass sample, the acanthopanax sample and the yam sample may be selected as fresh, dried or processed objects that have not been dried or exposed.

其中該珊瑚草樣本較佳係以冷凍乾燥,獲得一珊瑚草乾燥物。The coral grass sample is preferably freeze-dried to obtain a dried coral grass.

其中該山藥樣本較佳係以熱烘乾燥,獲得一山藥乾燥物。The yam sample is preferably dried by heat to obtain a dried yam.

其中該萃取步驟之珊瑚草樣本較佳係包含珊瑚草的全草部位。Preferably, the coral grass sample of the extraction step comprises a whole grass part of coral grass.

其中該萃取步驟之刺五加樣本較佳係包含刺五加的根部或莖部。Preferably, the acanthopanax sample of the extraction step comprises a root or stem of Acanthopanax senticosus.

其中該萃取步驟之山藥樣本較佳係包含山藥的塊莖部位。The yam sample of the extraction step preferably comprises a tuber part of yam.

其中該萃取步驟之溫度較佳為60~90℃。The temperature of the extraction step is preferably from 60 to 90 °C.

其中該萃取步驟較佳係萃取8~10小時。The extraction step is preferably 8 to 10 hours of extraction.

一種用以降血脂的醫藥組合物,包含:如申請專利範圍第1至10項之任一項所述之中草藥萃取混合物;及一醫藥學上可接受之載劑或賦形劑,使該中草藥萃取混合物成型為該醫藥組合物。A pharmaceutical composition for lowering blood fat, comprising: a herbal extract mixture according to any one of claims 1 to 10; and a pharmaceutically acceptable carrier or excipient for extracting the herbal extract The mixture is shaped into the pharmaceutical composition.

其中該中草藥萃取混合物之劑量較佳係150~600毫克。The dosage of the Chinese herbal medicine extract mixture is preferably 150-600 mg.

其中該醫藥組合物的類型較佳係錠劑、膠囊、粉劑、粒劑或液劑。Among them, the type of the pharmaceutical composition is preferably a tablet, a capsule, a powder, a granule or a liquid.

為讓本發明之上述及其他目的、特徵及優點能更明顯易懂,下文特舉本發明之較佳實施例,並配合所附圖式,作詳細說明如下:The above and other objects, features and advantages of the present invention will become more <RTIgt;

本發明之用以降血脂的中草藥萃取混合物,係包含來自珊瑚草、刺五加及山藥之中草藥萃取物,該珊瑚草、該刺五加及該山藥之中草藥萃取物以一特定比例混合,特別係以重量百分比為33.4~77.7%之珊瑚草萃取物、重量百分比為11.14~33.3%之刺五加萃取物及重量百分比為11.14~33.3%之山藥萃取物之比例混合之中草藥萃取混合物,係能夠有效降低血液中的總膽固醇(Total cholesterol,簡稱TC)、總三酸甘油酯(Total triglyceride,簡稱TG)及低密度脂蛋白膽固醇(Low-density lipoprotein cholesterol,簡稱LDL-C),且能夠抑制脂肪細胞的脂肪蓄 積,進而達到降低腦心血管疾病發生的風險。珊瑚草、刺五加或是山藥皆有血脂調降之作用,但以中醫藥性觀點,珊瑚草藥性偏涼,不適合高血脂症的病人長期使用,因易引起消化系統不適的症狀,若能輔以刺五加補氣以及山藥健脾胃之效力,即能減少單獨服用珊瑚草引致體寒的機率,並有助於降血脂功效的提升。The Chinese herbal medicine extract mixture for reducing blood fat of the present invention comprises a herbal extract from coral grass, acanthopanax senticosus and yam, and the coral grass, the acanthopanax senticosus and the yam herbal extract are mixed in a specific ratio, in particular A mixture of 33.4 to 77.7% by weight of coral grass extract, 11.14 to 33.3% by weight of Acanthopanax senticosus extract and 11.14 to 33.3% by weight of yam extract, mixed with a herbal extract mixture, can be effective Lowering total cholesterol (Total cholesterol, TC for short), Total triglyceride (TG) and Low-density lipoprotein cholesterol (LDL-C), and inhibiting fat cells Fat storage In order to reduce the risk of cardiovascular disease. Coral grass, acanthopanax or yam have the effect of lowering blood lipids, but from the perspective of traditional Chinese medicine, corals are herbally cool, not suitable for long-term use of patients with hyperlipidemia, because of symptoms that may cause digestive discomfort, if they can supplement With the effect of acanthopanax senticosus and yam spleen and stomach, it can reduce the chance of causing body cold by taking coral grass alone, and contribute to the improvement of blood fat lowering effect.

本發明之用以降血脂的中草藥萃取混合物可應用於製備降血脂的醫藥組合物,將本發明之用以降血脂的中草藥萃取混合物與醫藥學上可接受之載劑或賦形劑組合,形成一醫藥組合物,該醫藥組合物的類型可以為錠劑、膠囊、粉劑、粒劑或液劑等型式,提供個體以口服方式服用。The Chinese herbal medicine extract mixture for reducing blood fat of the present invention can be applied to prepare a hypolipidemic pharmaceutical composition, and the Chinese herbal medicine extract mixture for reducing blood fat of the present invention is combined with a pharmaceutically acceptable carrier or excipient to form a medicine. A composition, which may be in the form of a tablet, a capsule, a powder, a granule or a liquid, and is provided for oral administration by an individual.

請參照第1圖所示,本發明之用以降血脂的中草藥萃取混合物中的珊瑚草萃取物、刺五加萃取物與山藥萃取物,係經由下列方式製備,包含有:一萃取步驟S1、一濃縮步驟S2及一混合步驟S3。Referring to FIG. 1 , the coral grass extract, the acanthopanax extract and the yam extract in the Chinese herbal medicine extract mixture for reducing blood fat of the present invention are prepared by the following method, comprising: an extraction step S1, a Step S2 is concentrated and a mixing step S3 is performed.

該萃取步驟S1,係以水作為萃取溶劑,分別對珊瑚草樣本、刺五加樣本及山藥樣本進行萃取,而獲得一珊瑚草萃取液、一刺五加萃取液及一山藥萃取液,其中,該萃取溶劑與該珊瑚草樣本、該刺五加樣本及該山藥樣本之重量比例為1:8~1:12。更詳言之,該萃取溶劑係分別與該珊瑚草樣本、該刺五加樣本及該山藥樣本以1:5之重量比例進行萃取,以提高該萃取溶劑之萃取效率,又不會耗費過多萃取溶劑,以降低該萃取步驟S1之溶劑成本。The extraction step S1 uses water as an extraction solvent to extract a coral grass sample, a acanthopanax sample and a yam sample, respectively, to obtain a coral grass extract, a acanthopanax extract and a yam extract, wherein The weight ratio of the extraction solvent to the coral grass sample, the acanthopanax sample and the yam sample is 1:8 to 1:12. More specifically, the extraction solvent is extracted with the coral grass sample, the acanthopanax sample and the yam sample at a weight ratio of 1:5, respectively, to improve the extraction efficiency of the extraction solvent without excessive extraction. Solvent to reduce the solvent cost of the extraction step S1.

本實施例中,該珊瑚草樣本係可以選擇為Eucheuma okamurai Yamada的全草部位,其中,該珊瑚草樣本中的多 醣類為主要的生理活性成分,其分子量為500道耳吞(Dalton),係葡萄醣和木醣、半乳醣等單醣類的聚合體;該刺五加樣本係可以選擇為Acanthopanax senticosus 的根部或莖部,其中,該刺五加樣本中的紫丁香苷(Syringin)為主要的活性成分;該山藥樣本係可以選擇為台農一號(Dioscorea alata L.cv.Tainong 1)或台農二號(D.alata L.cv.Tainong 2)的塊根部位,其中,該山藥樣本中的皂苷(Diosgenin)為主要的活性成分。In this embodiment, the coral grass sample can be selected as the whole grass part of Eucheuma okamurai Yamada, wherein the polysaccharide in the coral grass sample is the main physiological active ingredient, and the molecular weight is 500 Dalton. It is a polymer of monosaccharides such as glucose and xylose, galactose, etc.; the acanthopanax senticosus sample can be selected as the root or stem of Acanthopanax senticosus , wherein the syringin in the acanthopanax senticosus sample is The main active ingredient; the yam sample line can be selected as the root part of Dioscorea alata L.cv.Tainong 1 or D.alata L.cv.Tainong 2, wherein the yam The saponin (Diosgenin) in the sample is the main active ingredient.

更詳言之,該珊瑚草樣本、刺五加樣本及山藥樣本可以選擇為未經乾燥或曝曬的鮮品、乾燥物或炮製物,以提高三種中草藥樣本中的活性成分含量。舉例而言,本實施例之珊瑚草樣本較佳係經冷凍乾燥處理24小時之乾燥物;本實施例之山藥樣本較佳係以熱烘法(50℃下熱烘24小時)處理之乾燥物,此炮製法有助於活性成皂苷的釋出。More specifically, the Coral Grass Sample, Acanthopanax Senticosus and Yam Samples can be selected as fresh, dried or processed foods that have not been dried or exposed to enhance the active ingredient content of the three Chinese herbal medicine samples. For example, the coral grass sample of the present embodiment is preferably a dried product which has been subjected to freeze-drying treatment for 24 hours; the yam sample of the present embodiment is preferably a dried product which is treated by a heat baking method (hot baking at 50 ° C for 24 hours). This method of preparation contributes to the release of active saponins.

本實施例較佳係於溫度為40~60℃下進行萃取6~10小時,以確保各中草藥樣本之活性成分不會因溫度過高而破壞,又能夠使各中草藥樣本的活性成分溶於該萃取溶劑中,此外,較佳係以震盪萃取輔助各中草藥樣本之活性成分溶於該萃取溶劑中。藉此,可將珊瑚草、刺五加及山藥中用以降血脂的活性成分萃取至該萃取溶劑中,以便於將各該萃取液製備成一用以降血脂之醫藥組合物。This embodiment is preferably carried out at a temperature of 40 to 60 ° C for 6 to 10 hours to ensure that the active ingredients of each Chinese herbal medicine sample are not destroyed by excessive temperature, and the active ingredients of each Chinese herbal medicine sample can be dissolved therein. In the extraction solvent, in addition, it is preferred to use an oscillating extraction to assist the active ingredients of each Chinese herbal medicine sample to be dissolved in the extraction solvent. Thereby, the active ingredients for lowering blood fat in coral grass, acanthopanax senticosus and yam can be extracted into the extraction solvent, so that each of the extracts can be prepared into a pharmaceutical composition for lowering blood fat.

本實施例選擇以水做為萃取溶劑,並於溫度50℃下分別對經乾燥的珊瑚草樣本、刺五加樣本及山藥樣本進行萃取,其萃取時間皆為8小時,較佳係重複萃取3次,並去除珊瑚草樣本、刺五加樣本及山藥樣本的萃餘物,分別得 到該珊瑚草萃取液、該刺五加萃取液與該山藥萃取液。藉此,可將珊瑚草、刺五加與山藥中用以降血脂之活性成分,分別萃取至該珊瑚草萃取液、該刺五加萃取液與該山藥萃取液中。In this embodiment, water is used as an extraction solvent, and the dried coral grass sample, the acanthopanax sample and the yam sample are respectively extracted at a temperature of 50 ° C, and the extraction time is 8 hours, preferably repeated extraction 3 And remove the remnants of the coral grass sample, the acanthopanax sample and the yam sample, respectively The coral grass extract, the acanthopanax extract and the yam extract are added. Thereby, the active ingredients for reducing blood fat in the coral grass, acanthopanax senticosus and yam can be separately extracted into the coral grass extract, the acanthopanax extract and the yam extract.

該濃縮步驟S2,係分別將該珊瑚草萃取液、該刺五加萃取液與該山藥萃取液進行濃縮,分別得到一珊瑚草萃取物、一刺五加萃取物與一山藥萃取物。舉例而言,該濃縮步驟S2係可選擇以減壓濃縮、蒸發或加熱乾燥方式進行濃縮,但不以此為限。本實施例係以減壓濃縮去除該珊瑚草萃取液、該刺五加萃取液與該山藥萃取液之萃取溶劑,分別得到該珊瑚草萃取物、該刺五加萃取物與該山藥萃取物。藉此,可提升該珊瑚草萃取物、該刺五加萃取物與該山藥萃取物中降血脂活性成分的效果。In the concentration step S2, the coral grass extract, the acanthopanax extract and the yam extract are respectively concentrated to obtain a coral grass extract, a acanthopanax extract and a yam extract. For example, the concentration step S2 can be selected by concentration under reduced pressure, evaporation or heat drying, but not limited thereto. In this embodiment, the coral grass extract, the acanthopanax extract and the extract solvent of the yam extract are removed by concentration under reduced pressure to obtain the coral grass extract, the acanthopanax extract and the yam extract, respectively. Thereby, the effect of the coral grass extract, the acanthopanax extract and the hypolipidemic active ingredient in the yam extract can be improved.

該混合步驟S3,將該珊瑚草萃取物、該刺五加萃取物與該山藥萃取物混合成一中草藥萃取混合物,其中,該珊瑚草萃取物佔該中草藥萃取混合物之重量百分比為33.4~77.7%、該刺五加萃取物為11.14~33.3%及該山藥萃取物為11.14~33.3%。更詳言之,當該珊瑚草萃取物之重量百分比為71.4%,刺五加萃取物及山藥萃取物之重量百分比分別為14.3%,各中草藥萃取物之間不會產生互相牴觸的抑制作用,且各中草藥萃取物之間能夠產生更佳的協同作用,發揮加乘的穩定血脂及抑制脂肪累積的效果。如此,本發明之用以降血脂的中草藥萃取混合物能夠降低血液中TC、TG或LDL-C之效果,並抑制脂肪細胞中累積脂質,進而達到降低罹患腦心血管疾病風險的功效In the mixing step S3, the coral grass extract, the acanthopanax extract and the yam extract are mixed into a Chinese herbal medicine extract mixture, wherein the coral grass extract accounts for 33.4 to 77.7% by weight of the Chinese herbal medicine extract mixture. The extract of Acanthopanax senticosus is 11.14~33.3% and the extract of the yam is 11.14~33.3%. More specifically, when the weight percentage of the coral grass extract is 71.4%, the weight percentage of the extract of Acanthopanax senticosus and the extract of yam is 14.3%, respectively, and there is no mutual inhibition between the extracts of the Chinese herbal medicines. Moreover, each of the Chinese herbal medicine extracts can produce a better synergistic effect, and the effect of stabilizing blood lipids and inhibiting fat accumulation can be exerted. Thus, the Chinese herbal medicine extract mixture for lowering blood fat of the present invention can reduce the effect of TC, TG or LDL-C in blood, and inhibit the accumulation of lipids in fat cells, thereby achieving the effect of reducing the risk of cardiovascular diseases in the brain.

本發明之用以降血脂的中草藥萃取混合物可以進一步以一醫藥學上可接受之載劑或賦形劑,使該中草藥萃取混合物成型為一醫藥組合物,較佳係一種口服劑型,如錠劑、膠囊、粉劑、粒劑或液劑;或者將本發明之用以降血脂的中草藥萃取混合物與其他食品或飲料組合,以一適於食用之樣態供生物體以口服方式服用。The Chinese herbal medicine extract mixture for reducing blood fat of the present invention may further form the Chinese herbal medicine extract mixture into a pharmaceutical composition, preferably an oral dosage form, such as a lozenge, by a pharmaceutically acceptable carrier or excipient. Capsules, powders, granules or liquid preparations; or the Chinese herbal medicine extract mixture for reducing blood fat of the present invention is combined with other foods or beverages, and is administered orally to the living body in an edible form.

為證實本發明之用以降血脂的中草藥萃取混合物具有穩定血脂參數及抑制脂肪細胞蓄積脂質之功效,以下係根據上述方法製備含有不同比例珊瑚草、刺五加及山藥的中草藥萃取物進行下列試驗,藉以說明本發明之中草藥萃取混合物對於穩定血液中TC、TG、高密度脂蛋白膽固醇(High-density lipoprotein cholesterol,簡稱HDL-C)及LDL的效果,以及各比例中草藥萃取混合物用以抑制脂肪細胞中脂質蓄積的作用。In order to confirm that the Chinese herbal medicine extract mixture for reducing blood fat of the present invention has the functions of stabilizing blood lipid parameters and inhibiting accumulation of lipids by fat cells, the following tests are prepared according to the above method for preparing Chinese herbal extracts containing different proportions of coral grass, acanthopanax senticosus and yam. To illustrate the effect of the herbal extract mixture of the present invention on stabilizing blood TC, TG, high-density lipoprotein cholesterol (HDL-C) and LDL, and the ratio of Chinese herbal medicine extract mixture for inhibiting fat cells. The role of lipid accumulation.

(A)脂肪細胞蓄積脂質試驗(A) Fat cell accumulation lipid test

本實施例係以3T3-L1脂肪細胞(購自台灣新竹食品工業發展研究所菌種中心,編號為BCRC 60159)作為測試平台,分別添加不同中草藥萃取混合物的比例及不同濃度之中草藥萃取混合物,觀察各組細胞中脂質蓄積的抑制狀況。In this example, 3T3-L1 fat cells (purchased from the Taiwan Hsinchu Food Industry Development Research Institute, BCRC 60159) were used as test platforms, and the ratios of different Chinese herbal extract mixtures and different concentrations of herbal extracts were observed. The inhibition of lipid accumulation in each group of cells.

更詳言之,本實施例係提供11組3T3-L1脂肪細胞(各組細胞數為1×104 cells/ml),於溫度37℃及5%之二氧化碳氣體之條件下共同培養24小時後,再添加如第1表所示之共培養物(每毫升培養液添加500μg之中草藥萃取混合物)培養24小時後,以油紅染色法觀察各組細胞的脂質蓄積情 況,並將各組細胞的脂質蓄積定量,其中,第A1-1組係添加該萃取溶劑(水)作為對照組,其無添加任何中草藥萃取混合物。More specifically, this example provides 11 sets of 3T3-L1 adipocytes (the number of cells in each group is 1×10 4 cells/ml), and co-cultured for 24 hours at a temperature of 37 ° C and 5% carbon dioxide gas. Then, the co-cultures as shown in Table 1 (500 μg of the herbal extract mixture per ml of the culture solution) were added for 24 hours, and the lipid accumulation of each group of cells was observed by oil red staining, and the cells of each group were observed. The lipid accumulation was quantitatively determined, wherein the extraction solvent (water) was added as the control group in the A1-1 group, and no Chinese herbal extract mixture was added.

比較第2a至2k圖,第A1-1組(第2a圖)之脂肪細胞並未與任何中草藥萃取混合物共培養,該第A1-1組之脂肪細胞油紅染色的區域面積明顯大於其他組,而第A1-2至A1-4組係分別添加500μg/ml之珊瑚草萃取物(第2b 圖)、500μg/ml之刺五加萃取物(第2c圖)或500μg/ml之山藥萃取物(第2d圖),雖然其脂肪細胞中脂質的量較第A1-1組為低,但其脂質含量仍高於第A1-5至A1-11組。Comparing the 2a to 2k maps, the fat cells of the A1-1 group (Fig. 2a) were not co-cultured with any Chinese herbal extract mixture, and the area of the red staining of the fat cells of the A1-1 group was significantly larger than that of the other groups. The A1-2 to A1-4 groups were each added with 500 μg/ml of Coral Grass Extract (2b). Figure), 500μg/ml of Acanthopanax senticosus extract (Fig. 2c) or 500μg/ml of yam extract (Fig. 2d), although the amount of lipid in the fat cells is lower than that of the A1-1 group, The lipid content was still higher than the A1-5 to A1-11 groups.

請參照第3圖,係各組脂肪細胞中的脂質量化長條圖,係以第A1-1組為基準(脂質蓄積百分率為100%),其中,第A1-5至A1-11組的脂肪細胞中的脂質含量明顯低於第A1-1至A1-4組。由此可知,本發明用以降血脂之中草藥萃取混合物,確實能夠藉由珊瑚草、刺五加及山藥萃取物的協同作用而達到降低脂肪細胞堆積脂質的效果。Please refer to Figure 3 for the lipid quantitative bar graph of each group of fat cells, based on group A1-1 (percent lipid percentage 100%), wherein the fat of group A1-5 to group A-11 The lipid content in the cells was significantly lower than in the A1-1 to A1-4 groups. It can be seen that the herb extracting mixture for reducing blood fat in the present invention can effectively reduce the accumulation of lipids in fat cells by the synergistic action of coral grass, acanthopanax senticosus and yam extract.

本實施例另取8組3T3-L1脂肪細胞(各組細胞數為1×104 cells/ml),於溫度37℃及5%之二氧化碳氣體之條件下共同培養24小時後,再添加如第2表所示之不同濃度之內容物培養24小時後,以油紅染色法觀察各組細胞的脂質蓄積情況,並將各組細胞的脂質蓄積定量,其中,第A2-1組係添加該萃取溶劑(水)作為對照組,其無添加任何中草藥萃取混合物。In this embodiment, another group of 8T3-L1 fat cells (the number of cells in each group is 1×10 4 cells/ml) is co-cultured for 24 hours at a temperature of 37 ° C and 5% carbon dioxide gas, and then added as After culturing the contents of different concentrations shown in Table 2 for 24 hours, the lipid accumulation of each group of cells was observed by oil red staining, and the lipid accumulation of each group of cells was quantified, wherein the extract of the A2-1 group was added. The solvent (water) was used as a control group, and no Chinese herbal extract mixture was added.

請參照第4圖,係各組脂肪細胞中的脂質量化長條圖,其中添加100~700μg/ml之中草藥萃取混合物皆能夠降低脂肪細胞中累積的脂質含量。Please refer to Figure 4 for the lipid quantitative bar graph of each group of fat cells. Adding 100~700μg/ml herbal extract mixture can reduce the accumulated lipid content in fat cells.

請參照第5a至5f圖及第6圖,本實施例取第A2-1及A2-6組之脂肪細胞,分別於添加共培養物第3、6及8天時,以油紅染色法觀察該脂肪細胞中脂質的累積情形。Referring to Figures 5a to 5f and Figure 6, in this example, the fat cells of groups A2-1 and A2-6 were observed by oil red staining on days 3, 6 and 8 of the co-cultures. The accumulation of lipids in the fat cells.

由第5a至5f圖及第6圖可知,本發明確實能夠藉由珊瑚草萃取物、刺五加萃取物及山藥萃取物之間的加乘作用,而達到降低脂肪細胞堆積脂質的效果,且該中草藥萃取混合物之重量比例,又以珊瑚草萃取物、刺五加萃取物及山藥萃取物為5:1:1者,其降低脂肪細胞累積脂質的效果較佳。As can be seen from Figures 5a to 5f and Figure 6, the present invention can achieve the effect of reducing the accumulation of lipids in fat cells by the interaction between coral grass extract, acanthopanax extract and yam extract, and The weight ratio of the Chinese herbal medicine extract mixture is 5:1:1, which is a coral seed extract, an extract of Acanthopanax senticosus and a yam extract, and the effect of reducing lipid accumulation in fat cells is better.

(B)高血脂動物模式試驗(B) High blood lipid animal model test

本實施例係以購自國家實驗動物繁殖及研究中心的Golden Syrian雄性倉鼠進行試驗,該倉鼠係飼養於溫度(25±1℃)、光照(日照時間12小時)皆維持於正常範圍之環境,使倉鼠自由進食及飲水,直到滿四週齡,開始餵食高脂飼料(TestDiet® 5TJT,其含1%膽固醇),待飼養8週後 (即滿十二週齡大),作為本實施例之高血脂試驗鼠(High-fat diet-induced hamster,簡稱HFD倉鼠)以進行試驗(B)。此外,本實施例之試驗(B)中皆另設有一組正常倉鼠作為對照組(第B0組),其餵食歷程中皆係攝取正常飼料直到滿十二週齡。This example was tested in a Golden Syrian male hamster purchased from the National Laboratory Animal Breeding and Research Center, which was maintained at a temperature (25 ± 1 ° C) and illumination (12 hours of sunshine) maintained in a normal range. Allow hamsters to eat and drink freely, until four weeks old, start feeding high-fat diet (TestDiet® 5TJT, which contains 1% cholesterol), after 8 weeks of feeding (i.e., 12 weeks old), as a high-fat diet-induced hamster (HFD hamster) of the present example, was tested (B). In addition, in the test (B) of the present example, a group of normal hamsters were additionally provided as a control group (Group B0), and the feeding process was ingested until the age of 12 weeks.

「以不同萃取物餵食高血脂動物」"Feeding high-fat animals with different extracts"

本實施例係取以上述方式獲得十二週齡之4組HFD倉鼠(各組為8重複),以如第3表所示之餵食條件飼養持續8週,並紀錄其體重變化。更詳言之,每日係以給藥管分別餵食如第3表所示之餵食物,其中,第B1組則僅餵食水;第B2、B3及B4組之HFD倉鼠係分別餵食不同劑量(1.5、3.0及6.0克/公斤體重/天)之中草藥萃取混合物,其中,本實施例之中草藥萃取混合物係包含重量比例為5:1:1之珊瑚草萃取物、刺五加萃取物及山藥萃取物。In the present example, four groups of HFD hamsters of 12 weeks old (8 replicates in each group) were obtained in the above manner, and fed for 8 weeks under the feeding conditions as shown in Table 3, and their body weight changes were recorded. More specifically, the foods as shown in Table 3 were fed daily by the administration tube, wherein the group B1 was fed only with water; the HFD hamsters of groups B2, B3 and B4 were fed different doses respectively ( 1.5, 3.0 and 6.0 g / kg body weight / day) Chinese herbal medicine extract mixture, wherein the herbal extract mixture in the present embodiment comprises coral grass extract, acanthopanax extract and yam extract in a weight ratio of 5:1:1. Things.

請參照第4表所示,係本實施例第B0至B4組分別經8週後之血脂參數,該血脂參數分別為三酸甘油脂(TG)、總膽固醇(TC)、高密度脂蛋白膽固醇(HDL-C)及低密度脂蛋白膽固醇(LDL-C)。Please refer to the fourth table, which is the blood lipid parameters of the groups B0 to B4 of the present embodiment after 8 weeks, respectively. The blood lipid parameters are triglyceride (TG), total cholesterol (TC), and high-density lipoprotein cholesterol. (HDL-C) and low density lipoprotein cholesterol (LDL-C).

由第4表可知,第B2至B4組於8週後,其TC、TG及LDL-C值與第B1組相比較均有下降,第B2至B4組之體重與第B1組相較均具有顯著差異(p <0.05),且該血脂參數係與中草藥萃取混合物之濃度成正相關。將實驗倉鼠攝取中草藥萃取混合物的攝取量換算成60公斤成人的每日建議攝取量,係為150~600毫克。由此可知,本發明中草藥萃取混合物之濃度為1.5~6.0g/kg/day係具有降低各血脂參數及實驗倉鼠體重之效果。As can be seen from the fourth table, the TC, TG, and LDL-C values of the B2 to B4 groups decreased after 8 weeks, compared with the B1 group, and the body weight of the B2 to B4 groups was compared with the B1 group. Significant differences ( p < 0.05), and the lipid parameters were positively correlated with the concentration of the Chinese herbal extract mixture. The intake of the experimental hamster ingestion of the Chinese herbal extract mixture was converted to the recommended daily intake of 60 kg of adults, which was 150-600 mg. It can be seen that the concentration of the herbal extract mixture of the present invention is 1.5 to 6.0 g/kg/day, which has the effect of lowering the blood lipid parameters and the weight of the experimental hamster.

綜上所述,本發明之用以降血脂的中草藥萃取混合物係組合三種不同天然植物-珊瑚草、刺五加及山藥的活性 成分,藉由該三種中草藥萃取物以抑制脂肪細胞堆積脂質,並有助於抑制高血脂動物的血脂參數(如TG、TC及LDL-C),該中草藥萃取混合物的特定比例組合不僅不會相互抑制,反而具有協同作用並加乘各自之降血脂的功效。In summary, the Chinese herbal medicine extract mixture for reducing blood fat of the present invention combines the activities of three different natural plants - coral grass, acanthopanax senticosus and yam. Ingredients, the three Chinese herbal extracts inhibit lipid accumulation in fat cells, and help to inhibit blood lipid parameters (such as TG, TC, and LDL-C) in hyperlipidemia animals, and the specific ratio combinations of the Chinese herbal extract mixtures are not only not mutually Inhibition, on the contrary, has synergistic effects and adds the effects of reducing blood lipids.

綜上所述,將本發明之一有效劑量(如150~600毫克)的中草藥萃取混合物與至少一醫藥學上可接受之載劑或賦形劑組合,形成一醫藥組合物,該中草藥萃取混合物係以如第1圖所示之方法製備而成,較佳係每單位體重之個體投予150~600毫克/公斤體重,且其施予時間可持續8週,以達到穩定個體的血脂參數,並控制生物體之脂肪細胞蓄積脂肪之功效。此外,本發明用以降血脂之醫藥組合物之主要活性成分係來自於天然草本植物-珊瑚草、刺五加及山藥所萃取而得,因此對於生物體溫和且不具毒性,使用者不需擔心該醫藥組合物具有肝毒性,而能提高使用者服用該醫藥組合物之意願。In summary, an effective dosage (e.g., 150 to 600 mg) of the herbal extract mixture of the present invention is combined with at least one pharmaceutically acceptable carrier or excipient to form a pharmaceutical composition, the herbal extract mixture It is prepared by the method as shown in Fig. 1. It is preferred to administer 150-600 mg/kg body weight per unit body weight, and the administration time can last for 8 weeks to achieve stable blood lipid parameters. And control the effect of fat cells in the body to accumulate fat. In addition, the main active ingredient of the pharmaceutical composition for reducing blood fat of the present invention is derived from natural herbs - coral grass, acanthopanax senticosus and yam, so that the organism is mild and non-toxic, and the user does not need to worry about the The pharmaceutical composition has hepatotoxicity and can increase the user's willingness to take the pharmaceutical composition.

藉此,本發明之用以降血脂的中草藥萃取混合物,係藉由穩定血脂參數及抑制脂肪細胞累積脂質,進而達到有效降低腦心血管疾病罹患風險之功效。Thereby, the Chinese herbal medicine extract mixture for reducing blood fat of the present invention achieves the effect of effectively reducing the risk of cardiovascular and cardiovascular diseases by stabilizing blood lipid parameters and inhibiting accumulation of lipids by fat cells.

本發明之用以降血脂的中草藥萃取混合物,其係包含有珊瑚草、刺五加及山藥之萃取物,係具有抑制脂肪細胞累積脂質的加乘作用,以達到有效降血脂之功效。The Chinese herbal medicine extracting mixture for reducing blood fat of the invention comprises the extracts of coral grass, acanthopanax senticosus and yam, which has the effect of inhibiting the accumulation of lipids of fat cells to achieve the effect of effectively lowering blood fat.

本發明之用以降血脂的醫藥組合物,其係包含有珊瑚草、刺五加及山藥之萃取物,係能夠互相產生協同作用而達到有效提高降血脂效果之功效。The pharmaceutical composition for lowering blood fat of the present invention comprises an extract of coral grass, acanthopanax senticosus and yam, which can synergistically effect each other to achieve an effect of effectively improving blood fat lowering effect.

雖然本發明已利用上述較佳實施例揭示,然其並非用 以限定本發明,任何熟習此技藝者在不脫離本發明之精神和範圍之內,相對上述實施例進行各種更動與修改仍屬本發明所保護之技術範疇,因此本發明之保護範圍當視後附之申請專利範圍所界定者為準。Although the present invention has been disclosed using the above preferred embodiments, it is not In order to limit the scope of the present invention, it is still within the spirit and scope of the present invention that various modifications and changes to the above-described embodiments are still within the technical scope of the present invention. The scope defined in the patent application is subject to change.

S1‧‧‧萃取步驟S1‧‧‧ extraction step

S2‧‧‧濃縮步驟S2‧‧‧ Concentration step

S3‧‧‧混合步驟S3‧‧‧ mixing step

第1圖:本發明用以降血脂的中草藥萃取混合物中該珊瑚草萃取物、該刺五加萃取物及該山藥萃取物之製備步驟方塊圖。Fig. 1 is a block diagram showing the preparation steps of the coral grass extract, the acanthopanax extract and the yam extract in the Chinese herbal medicine extract mixture for reducing blood fat.

第2a圖:本實施例第A1-1組之脂肪細胞油紅染色照片。Figure 2a: Oil red staining of fatty cells in group A1-1 of this example.

第2b圖:本實施例第A1-2組之脂肪細胞油紅染色照片。Figure 2b: Oil red staining of fat cells in Group A1-2 of this example.

第2c圖:本實施例第A1-3組之脂肪細胞油紅染色照片。Figure 2c: Oil red staining of the fat cells of Group A1-3 of this example.

第2d圖:本實施例A1-4組之脂肪細胞油紅染色照片。Figure 2d: Oil red staining of fat cells of Group A1-4 of this example.

第2e圖:本實施例A1-5組之脂肪細胞油紅染色照片。Figure 2e: Photograph of the fat red staining of the fat cells of Group A1-5 of this example.

第2f圖:本實施例A1-6組之脂肪細胞油紅染色照片。Figure 2f: Oil red staining of fat cells of Group A1-6 of this example.

第2g圖:本實施例A1-7組之脂肪細胞油紅染色照片。Figure 2g: Oil red staining of fat cells of Group A1-7 of this example.

第2h圖:本實施例A1-8組之脂肪細胞油紅染色照片。Figure 2h: Oil red staining of fat cells of Group A1-8 of this example.

第2i圖:本實施例A1-9組之脂肪細胞油紅染色照片。Figure 2i: Oil red staining of fat cells of Group A1-9 of this example.

第2j圖:本實施例A1-10組之脂肪細胞油紅染色照片。Fig. 2j: Photograph of oil red staining of fat cells in the group A1-10 of this example.

第2k圖:本實施例A1-11組之脂肪細胞油紅染色照片。Figure 2k: Oil red staining of fat cells of Group A1-11 of this example.

第3圖:本實施例第A1-1至A1-11組之脂質蓄積相對百分率長條圖。Fig. 3 is a bar graph showing the relative percentage of lipid accumulation in the groups A1-1 to A1-11 of the present Example.

第4圖:本實施例第A2-1至A2-8組之脂質蓄積相對百分率長條圖。Fig. 4 is a bar graph showing the relative percentage of lipid accumulation in the groups A2-1 to A2-8 of the present Example.

第5a圖:本實施例第A2-1組經3天培養後之脂肪細胞油紅染色照片。Fig. 5a: Photograph of oil red staining of fat cells after 3 days of culture in the A2-1 group of the present Example.

第5b圖:本實施例第A2-1組經6天培養後之脂肪細胞油紅染色照片。Figure 5b: Photograph of oil red staining of fat cells after 6 days of culture in Group A2-1 of this example.

第5c圖:本實施例第A2-1組經8天培養後之脂肪細胞油紅染色照片。Fig. 5c: Photograph of oil red staining of fat cells after 8 days of culture in the A2-1 group of the present Example.

第5d圖:本實施例第A2-5組經3天培養後之脂肪細胞油紅染色照片。Figure 5d: Oil red staining of fat cells after 3 days of culture in Group A2-5 of this example.

第5e圖:本實施例第A2-5組經6天培養後之脂肪細胞油紅染色照片。Figure 5e: Oil red staining of fat cells after 6 days of culture in Group A2-5 of this example.

第5f圖:本實施例第A2-5組經8天培養後之脂肪細胞油紅染色照片。Fig. 5f is a photograph of oil red staining of fat cells after 8 days of culture in Group A2-5 of the present Example.

第6圖:本實施例第A2-1及A2-6組經不同培養天數後之吸光值OD500 長條圖。Fig. 6 is a bar graph of the absorbance OD 500 of the groups A2-1 and A2-6 of the present embodiment after different culture days.

S1‧‧‧萃取步驟S1‧‧‧ extraction step

S2‧‧‧濃縮步驟S2‧‧‧ Concentration step

S3‧‧‧混合步驟S3‧‧‧ mixing step

Claims (9)

一種用以降血脂的中草藥萃取混合物,係包含:一重量百分比為33.4~77.7%之珊瑚草萃取物;一重量百分比為11.14~33.3%之刺五加萃取物;及一重量百分比為11.14~33.3%之山藥萃取物;其中,該珊瑚草萃取物、該刺五加萃取物及該山藥萃取物係藉由下列步驟而製得:一萃取步驟,以水作為萃取溶劑,分別對珊瑚草樣本、刺五加樣本及山藥樣本進行萃取,而獲得一珊瑚草萃取液、一刺五加萃取液及一山藥萃取液,其中,該萃取溶劑分別與該珊瑚草樣本、該刺五加樣本及該山藥樣本之重量比例為1:8~1:12;一濃縮步驟,係分別將該珊瑚草萃取液、該刺五加萃取液與該山藥萃取液進行濃縮,分別得到一珊瑚草萃取物、一刺五加萃取物與一山藥萃取物;及一混合步驟,將該珊瑚草萃取物、該刺五加萃取物與該山藥萃取物混合成該中草藥萃取混合物;其中,該萃取步驟之珊瑚草樣本係包含珊瑚草的全草部位,該萃取步驟之刺五加樣本係包含刺五加的根部或莖部,且該萃取步驟之山藥樣本係包含山藥的塊根部位。 A Chinese herbal medicine extract mixture for lowering blood fat, comprising: a coralweed extract of 33.4 to 77.7% by weight; a scutellaria extract of 11.14 to 33.3% by weight; and a weight percentage of 11.14 to 33.3% Yam extract; wherein the coral grass extract, the acanthopanax extract and the yam extract are obtained by the following steps: an extraction step using water as an extraction solvent, respectively, on coral grass samples, thorns Five samples and yam samples were extracted to obtain a coral grass extract, a acanthopanax extract and a yam extract, wherein the extraction solvent and the coral grass sample, the acanthopanax sample and the yam sample respectively The weight ratio is 1:8~1:12; in a concentration step, the coral grass extract, the acanthopanax extract and the yam extract are respectively concentrated to obtain a coral grass extract and a thorn Adding the extract and a yam extract; and mixing the coral grass extract, the acanthopanax extract and the yam extract into the Chinese herbal medicine extract mixture; wherein the extracting step Shan Hucao whole plant parts of the sample line comprises Shan Hucao Acanthopanax the sample extraction system comprising the steps of Acanthopanax root or stem, and the yam sample extraction system comprising the steps of earthnuts yam. 如申請專利範圍第1項所述之用以降血脂的中草藥萃取混合物,其中該珊瑚草樣本、該刺五加樣本及該山藥樣本為未經乾燥或曝曬的鮮品、乾燥物或炮製物。 The Chinese herbal medicine extract mixture for lowering blood fat as described in claim 1, wherein the coral grass sample, the acanthopanax sample and the yam sample are fresh, dried or processed products which are not dried or exposed. 如申請專利範圍第2項所述之用以降血脂的中草藥萃 取混合物,其中該珊瑚草樣本係以冷凍乾燥,獲得一珊瑚草乾燥物。 Chinese herbal medicine extract for lowering blood fat as described in item 2 of the patent application scope The mixture was taken, and the coral grass sample was freeze-dried to obtain a dried coral grass. 如申請專利範圍第2項所述之用以降血脂的中草藥萃取混合物,其中該山藥樣本係以熱烘乾燥,獲得一山藥乾燥物。 The Chinese herbal medicine extract mixture for lowering blood fat as described in claim 2, wherein the yam sample is dried by heat to obtain a dried yam. 如申請專利範圍第1項所述之用以降血脂的中草藥萃取混合物,其中該萃取步驟之溫度為40~60℃。 The Chinese herbal medicine extract mixture for lowering blood fat as described in claim 1, wherein the temperature of the extraction step is 40 to 60 °C. 如申請專利範圍第1項所述之用以降血脂的中草藥萃取混合物,其中該萃取步驟係萃取6~10小時。 The Chinese herbal medicine extract mixture for lowering blood fat as described in claim 1, wherein the extraction step is extraction for 6 to 10 hours. 一種用以降血脂的醫藥組合物,包含:一如申請專利範圍第1項所述之中草藥萃取混合物;及一醫藥學上可接受之載劑或賦形劑,使該中草藥萃取混合物成型為該醫藥組合物。 A pharmaceutical composition for lowering blood fat, comprising: a herbal extract mixture as described in claim 1; and a pharmaceutically acceptable carrier or excipient to form the herbal extract mixture into the medicine combination. 如申請專利範圍第7項所述之用以降血脂的醫藥組合物,其中該中草藥萃取混合物之劑量係150~600毫克。 The pharmaceutical composition for lowering blood fat as described in claim 7 wherein the dosage of the Chinese herbal medicine extract mixture is 150-600 mg. 如申請專利範圍第7項所述之用以降血脂的醫藥組合物,其中該醫藥組合物的類型係錠劑、膠囊、粉劑、粒劑或液劑。A pharmaceutical composition for lowering blood fat as described in claim 7, wherein the pharmaceutical composition is in the form of a tablet, a capsule, a powder, a granule or a liquid.
TW101124040A 2012-07-04 2012-07-04 Herbal extract mixture for reducing blood lipid and a combination thereof TWI440465B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
TW101124040A TWI440465B (en) 2012-07-04 2012-07-04 Herbal extract mixture for reducing blood lipid and a combination thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TW101124040A TWI440465B (en) 2012-07-04 2012-07-04 Herbal extract mixture for reducing blood lipid and a combination thereof

Publications (2)

Publication Number Publication Date
TW201402139A TW201402139A (en) 2014-01-16
TWI440465B true TWI440465B (en) 2014-06-11

Family

ID=50345326

Family Applications (1)

Application Number Title Priority Date Filing Date
TW101124040A TWI440465B (en) 2012-07-04 2012-07-04 Herbal extract mixture for reducing blood lipid and a combination thereof

Country Status (1)

Country Link
TW (1) TWI440465B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9895400B2 (en) 2014-10-02 2018-02-20 Genmont Biotech Inc. Composition and use of Lactobacillus reuteri GMNL-263 in decreasing blood lipid levels

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9895400B2 (en) 2014-10-02 2018-02-20 Genmont Biotech Inc. Composition and use of Lactobacillus reuteri GMNL-263 in decreasing blood lipid levels

Also Published As

Publication number Publication date
TW201402139A (en) 2014-01-16

Similar Documents

Publication Publication Date Title
CN103417837B (en) Medlar health preserving cream of a kind of medicine-food two-purpose and preparation method thereof
WO2015172608A1 (en) Capsule for assisting in reducing blood fat and preparation method therefor
CN102551046B (en) Natural health composition for weight reduction and application of same
CN100579545C (en) Health-care wine with sleeping improving and beauty functions and its preparing process
CN106362020B (en) A kind of pine pollen composition and preparation method thereof with improvement defecating feces excretion
CN108014150A (en) Application of the natural drug composition in anti anoxia and radiation-resistant medicine or food is prepared
CN102188486B (en) Pharmaceutical composition for preventing and treating fatty liver and preparation method thereof
CN106177432A (en) A kind of health composition comprising leaf of Cyclocarya paliurus Iljinskaja, Folium Mori, green tea and Rhizoma Polygonati Odorati
CN101904501B (en) Functional food for relieving fatigue and preparation method thereof
CN108420890B (en) Composition with blood fat reducing effect and preparation method thereof
CN106692532A (en) Traditional Chinese medicine composition used for burning fat and losing weight as well as patch and weight losing package thereof
WO2019100843A1 (en) Enteromorpha prolifera polysaccharide composite blood lipid-lowering health care product and preparation method therefor
TWI440465B (en) Herbal extract mixture for reducing blood lipid and a combination thereof
CN106138155A (en) A kind of compositions preventing and treating hepatitis and application thereof
CN103920140A (en) Compound preparation for reducing blood glucose, body weight and fat for human
CN103720808B (en) A kind of composition and use thereof, preparation method with relieving constipation effect
CN102793767B (en) Radix notoginseng pharmaceutical composition for treating insomnia as well as preparation method and application of pharmaceutical composition
CN108904596B (en) Composition with memory improving effect
CN101816708B (en) Chinese medicinal composition for curing rheumatism and preparation method thereof
CN106177476A (en) A kind of Hyperglycemic health care compositions comprising Herba Dendrobii and Pericarpium Citri Reticulatae
CN100525804C (en) Chinese traditional medicine compound preparations having a function of slimming
CN110025011A (en) A kind of Radix Ophiopogonis ginseng lozenge of strengthen immunity
CN102579713B (en) Traditional Chinese medicine for treating children obesity and preparation method
CN109528827B (en) Pharmaceutical composition and preparation for promoting blood circulation, removing blood stasis and reducing blood fat and preparation method thereof
CN108478701A (en) A kind of lozenge of strengthen immunity